Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.1 HKD | -1.14% | +6.82% | -30.04% |
Apr. 25 | Ascentage Pharma to Present Four Studies at US Oncology Meet | MT |
Apr. 09 | Ascentage Pharma Chairman Boosts Stake in Firm | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-30.04% | 703M | - | ||
+3.25% | 106B | B+ | ||
+7.02% | 23.47B | B | ||
-14.98% | 21.9B | B+ | ||
-7.05% | 18.77B | A- | ||
-38.55% | 17.85B | A- | ||
-9.93% | 16.78B | B | ||
+5.80% | 14.41B | C+ | ||
+35.01% | 12.86B | C+ | ||
+319.13% | 8.78B | - | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6855 Stock
- Ratings Ascentage Pharma Group International